During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Eli Lilly continues to break new ground. Its famous weight loss medicine, Zepbound (tirzepatide), just became the first to ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Losing weight on a GLP-1 can lead to muscle loss, research shows. Here, obseity experts share how to preserve your lean ...

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...